Stocks
Outlook Therapeutics, Inc.OTLK
NASDAQHealthcareBiotechnology$0.52
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing an ophthalmic formulation of bevacizumab for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Its lead candidate, ONS-5010, is under regulatory review, and investor attention centers on approval timelines and commercial potential in the ophthalmology market.
52W Range: $0.16-$2.54
Congressional Interest in Outlook Therapeutics, Inc. (OTLK)
No congressional trades have been disclosed for Outlook Therapeutics, Inc. (OTLK) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading OTLK?
No congressional trades found for this stock.